Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies

被引:88
作者
Dahlgren, David [1 ]
Sjoblom, Markus [2 ]
Hellstrom, Per M. [3 ]
Lennernas, Hans [1 ]
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
[2] Uppsala Univ, Div Physiol, Dept Neurosci, Uppsala, Sweden
[3] Uppsala Univ, Dept Med Sci, Gastroenterol Hepatol, Uppsala, Sweden
基金
瑞典研究理事会;
关键词
chemotherapeutics-induced mucositis; gastrointestinal physiology; intestinal proliferation; cancer; stem cells; toxicity; mucositis; KERATINOCYTE GROWTH-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; GLUCAGON-LIKE PEPTIDE-2; ORAL MUCOSITIS; MUCOSAL PERMEABILITY; EPITHELIAL-CELLS; ANIMAL-MODEL; DNA-DAMAGE; IN-VIVO; MELATONIN;
D O I
10.3389/fphar.2021.681417
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gastrointestinal tract is particularly vulnerable to off-target effects of antineoplastic drugs because intestinal epithelial cells proliferate rapidly and have a complex immunological interaction with gut microbiota. As a result, up to 40-100% of all cancer patients dosed with chemotherapeutics experience gut toxicity, called chemotherapeutics-induced intestinal mucositis (CIM). The condition is associated with histological changes and inflammation in the mucosa arising from stem-cell apoptosis and disturbed cellular renewal and maturation processes. In turn, this results in various pathologies, including ulceration, pain, nausea, diarrhea, and bacterial translocation sepsis. In addition to reducing patient quality-of-life, CIM often leads to dose-reduction and subsequent decrease of anticancer effect. Despite decades of experimental and clinical investigations CIM remains an unsolved clinical issue, and there is a strong consensus that effective strategies are needed for preventing and treating CIM. Recent progress in the understanding of the molecular and functional pathology of CIM had provided many new potential targets and opportunities for treatment. This review presents an overview of the functions and physiology of the healthy intestinal barrier followed by a summary of the pathophysiological mechanisms involved in the development of CIM. Finally, we highlight some pharmacological and microbial interventions that have shown potential. Conclusively, one must accept that to date no single treatment has substantially transformed the clinical management of CIM. We therefore believe that the best chance for success is to use combination treatments. An optimal combination treatment will likely include prophylactics (e.g., antibiotics/probiotics) and drugs that impact the acute phase (e.g., anti-oxidants, apoptosis inhibitors, and anti-inflammatory agents) as well as the recovery phase (e.g., stimulation of proliferation and adaptation).
引用
收藏
页数:12
相关论文
共 132 条
[1]   The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs [J].
Abramovitz, M ;
Adam, M ;
Boie, Y ;
Carrière, MC ;
Denis, D ;
Godbout, C ;
Lamontagne, S ;
Rochette, C ;
Sawyer, N ;
Tremblay, NM ;
Belley, M ;
Gallant, M ;
Dufresne, C ;
Gareau, Y ;
Ruel, R ;
Juteau, H ;
Labelle, M ;
Ouimet, N ;
Metters, KM .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1483 (02) :285-293
[2]   Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad [J].
Ahluwalia, Bani ;
Magnusson, Maria K. ;
Ohman, Lena .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (11) :1185-1193
[3]   Emerging evidence on the pathobiology of mucositis [J].
Al-Dasooqi, Noor ;
Sonis, Stephen T. ;
Bowen, Joanne M. ;
Bateman, Emma ;
Blijlevens, Nicole ;
Gibson, Rachel J. ;
Logan, Richard M. ;
Nair, Raj G. ;
Stringer, Andrea M. ;
Yazbeck, Roger ;
Elad, Sharon ;
Lalla, Rajesh V. .
SUPPORTIVE CARE IN CANCER, 2013, 21 (07) :2075-2083
[4]   Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat [J].
Al-Dasooqi, Noor ;
Bowen, Joanne M. ;
Gibson, Rachel J. ;
Logan, Richard M. ;
Stringer, Andrea M. ;
Keefe, Dorothy M. .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2011, 92 (05) :357-365
[5]   Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat [J].
Al-Dasooqi, Noor ;
Gibson, Rachel J. ;
Bowen, Joanne M. ;
Logan, Richard M. ;
Stringer, Andrea M. ;
Keefe, Dorothy M. .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2010, 235 (10) :1244-1256
[6]  
[Anonymous], 2009, J SUPPORT ONCOL
[7]   Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer [J].
Antonadou, D ;
Pepelassi, M ;
Synodinou, M ;
Puglisi, M ;
Throuvalas, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (03) :739-747
[8]   The biology of innate lymphoid cells [J].
Artis, David ;
Spits, Hergen .
NATURE, 2015, 517 (7534) :293-301
[9]   Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders [J].
Auld, Fiona ;
Maschauer, Emily L. ;
Morrison, Ian ;
Skene, Debra J. ;
Riha, Renata L. .
SLEEP MEDICINE REVIEWS, 2017, 34 :10-22
[10]   GASTROINTESTINAL SURFACE PROTECTION AND MUCOSA RECONDITIONING [J].
BENGMARK, S ;
JEPPSSON, B .
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 1995, 19 (05) :410-415